Cancer Therapy: Preclinical

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Mike I. Walton1, Paul D. Eve1, Angela Hayes1, Melanie R. Valent1, Alexis K. De Haven Brandon1, Gary Box1, Albert Hallsworth1, Elizabeth L. Smith1, Kathy J. Boxall1, Michael Lainchbury1, Thomas P. Matthews1, Yann Jamin2, Simon P. Robinson2, G. Wynne Aherne1, John C. Reader3, Louis Chesler1, Florence I. Raynaud1, Suzanne A. Eccles1, Ian Collins1, and Michelle D. Garrett1

Abstract

Purpose: Many tumors exhibit defective cell-cycle checkpoint control and increased replicative stress. CHK1 is critically involved in the DNA damage response and maintenance of replication fork stability. We have therefore discovered a novel potent, highly selective, orally active ATP-competitive CHK1 inhibitor, CCT244747, and present its preclinical pharmacology and therapeutic activity.

Experimental Design: Cellular CHK1 activity was assessed using an ELISA assay, and cytotoxicity a SRB assay. Biomarker modulation was measured using immunoblotting, and cell-cycle effects by flow cytometry analysis. Single-agent oral CCT244747 antitumor activity was evaluated in a MYCN-driven transgenic mouse model of neuroblastoma by MRI and in genotoxic combinations in human tumor xenografts by growth delay.

Results: CCT244747 inhibited cellular CHK1 activity (IC50 29–170 nmol/L), significantly enhanced the cytotoxicity of several anticancer drugs, and abrogated drug-induced S and G2 arrest in multiple tumor cell lines. Biomarkers of CHK1 (pS296 CHK1) activity and cell-cycle inactivity (pY15 CDK1) were induced by genotoxics and inhibited by CCT244747 both in vitro and in vivo, producing enhanced DNA damage and apoptosis. Active tumor concentrations of CCT244747 were obtained following oral administration. The antitumor activity of both gemcitabine and irinotecan were significantly enhanced by CCT244747 in several human tumor xenografts, giving concomitant biomarker modulation indicative of CHK1 inhibition. CCT244747 also showed marked antitumor activity as a single agent in a MYCN-driven neuroblastoma.

Conclusion: CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies.

Clin Cancer Res; 18(20); 5650–61. ©2012 AACR.

Introduction

The maintenance of genomic integrity is critical for cell survival and proliferation (1). DNA damage can arise from either intrinsic processes, such as oxidative stress or replication errors, or exogenous sources such as environmental mutagens (1, 2). Cells respond to genomic stress by activating a number of cell-cycle checkpoints as part of the DNA damage response (DDR) to facilitate cell-cycle arrest, DNA repair, or apoptosis (3, 4). The DDR effector kinase CHK1 has been shown to activate the G1 and G2 checkpoints by modulating the expression and function of CDC25 A and C, respectively (5, 6). In addition, CHK1 has an important role in the S-phase checkpoint where it stabilizes and preserves replication fork complexes following replicative stress, preventing catastrophic replication fork collapse (5, 7). CHK1 is also involved in homologous recombination repair of DNA through activation of Rad51 (8) and mitosis through direct phosphorylation of Aurora B (9).

Many tumor cells exhibit an incomplete DDR and harbor defects in genes controlling cell-cycle checkpoints and DNA repair (10). P53 is frequently deregulated in human cancers leading to compromised G1-S arrest and DNA repair (11). Consequently it has been argued that CHK1 inhibitors may selectively enhance the activity of genotoxic agents in tumors by abrogating the S and G2
Translational Relevance

CCT244747 is a novel potent, highly selective, and orally active CHK1 inhibitor that significantly increased the cytotoxicity of several chemotherapeutic agents in vitro. CCT244747 clearly inhibited genotoxic-induced biomarkers for CHK1 (pS296 CHK1) activity and CDK1 (pY15 CDK1) inactivity in vitro and in vivo, resulting in enhanced DNA damage and apoptosis. Scheduling studies showed CCT244747 must be present 24 to 48 hours following genotoxic exposure for maximum potentiation. Potentially therapeutic concentrations of CCT244747 were readily achieved in tumors following oral administration. Gemcitabine and irinotecan antimetabolites were significantly enhanced by delayed and repeated CCT244747 administration, a requirement greatly facilitated through its oral bioavailability. Moreover, CCT244747 showed marked antitumor activity as an orally administered single agent in a MYCN-driven transgenic model of neuroblastoma. In conclusion, CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor that justifies further evaluation as a single agent and in combination with genotoxic anticancer therapies.

checkpoints, whereas normal cells will be rescued because of their competent DDR (5, 12, 13). Studies using CHK1 RNAi and selective CHK1 inhibitors have provided evidence that this is the case for certain chemotherapeutic agents such as topoisomerase inhibitors and antimitabolites (14–17). On the basis of these data, a number of CHK1 inhibitors have been developed and are currently undergoing clinical evaluation in combination with specific genotoxic drugs (5, 12, 13, 17).

Accumulating evidence indicates that the activation of a number of oncogenes such as MYC and RAS, can give rise to enhanced replicative stress in tumors due to increased initiation and firing of replication origins in the DNA (1, 18, 19). In view of the essential role of CHK1 in the preservation of replication fork stability, it has been suggested that CHK1 inhibitors may have single-agent activity in defined tumor backgrounds exhibiting high levels of replicative stress (4, 20, 21). This concept has been consolidated using CHK1 RNAi and several CHK1 inhibitors in tumor types as diverse as acute myelogenous leukemia (AML), C-MYC–driven lymphomas, MYCN-regulated neuroblastomas, and various solid tumors (17, 20, 22–24). Consequently, CHK1 inhibitors are increasingly attractive potential anticancer agents (5, 12, 13, 25).

In this report, we present the preclinical pharmacology, therapeutic activity, and pharmacodynamic biomarker profile of the novel selective and orally bioavailable CHK1 inhibitor CCT244747 in combination with various genotoxic agents. Moreover, we provide clear evidence that CCT244747 has potent single-agent antitumor activity in a spontaneous, MYCN-driven transgenic mouse model of neuroblastoma. These data represent the first disclosure, with chemical structure, of an orally active, potent, and highly selective CHK1 inhibitor and support the development of this class of compounds as therapeutic agents either alone or in combination with genotoxic anticancer drugs.

Materials and Methods

Drugs and treatments

CCT244747 was synthesized as previously described (26). Gemcitabine and irinotecan were obtained from Eli Lilly and Pfizer respectively and used as clinical formulations. SN38, the active metabolite of irinotecan, was purchased from LKT laboratories for in vitro studies. All other compounds were purchased from Sigma.

Tissue culture

The p53 mutant colon tumor cell lines SW620 (p53−/−, KRAS−/−, APC−/−, SMAD4−/−, and MAP2K4−/−) and HT29 (p53−/−, APC−/−, PIK3CA−/−, BRAF−/−, and SMAD4−/−), the p53 mutant pancreatic cancer cell line MiaPaCa-2 (p53−/−, KRAS−/−, KDM6A−/−, CDKN2a−/−, and CDKN2A−/−) and the p53 mutant non–small cell lung cancer Calu6 cells (p53−/− and KRAS−/−) were purchased from the American Type Culture Collection (Lot numbers 4487729, 3924081, 57866607, and 58683029, respectively, and Sanger Centre data http://www.sanger.ac.uk/genetics/CGP/cosmic). Cells were grown in Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum and 2 mmol/L glutamine under a humidified atmosphere of 5% CO2:air at 37°C. Cells were cultured for less than 6 months before renewal from early passage, frozen stocks. All cell lines were shown to be mycoplasma free using a PCR-based assay (VenorGeM, Minerva Biolabs).

In vitro kinase assays

In vitro kinase assays were carried out commercially at 1 and 10 μmol/L CCT244747, with ATP concentrations corresponding to the kinase Km against 120 to 140 human kinases (MRP phosphorylation unit, Dundee). Additional IC50 determinations for FLT3 and CHK2 were carried out using a commercial assay (Z-Lyte, Invitrogen) or in-house with recombinant human CHK1, on an Ezreader II (Caliper Life Sciences) or CDK1 in a DELFIA assay (Perkin-Elmer).

In vitro cytotoxicity, potentiation, and G2 checkpoint abrogation assays

All assays were conducted as described previously (27). Cytotoxicity was determined as the growth inhibition 50% (GI50) using a standard 96-hour incubation (i.e., 4 cell doublings) and sulphorhodamine B (96-hour SRB) staining. Potentiation studies were carried out using CCT244747 alone to determine the GI50 of CCT244747 or in combination with a fixed GI50 concentration of the genotoxic to determine the combination GI50 of CCT244747. This approach was validated using gemcitabine in SW620 and shown to be a simple, robust, and sensitive assay of CHK1 inhibitor potentiation activity (refs. 27, 28; see Supplementary Fig. S1). For contact time studies, cells were
treated with a fixed GI50 concentration of gemcitabine combined with different concentrations of CCT244747, and at appropriate times, medium was removed and replaced with either fresh medium or medium containing gemcitabine alone and incubated up to 96 hours. The ability of CCT244747 to enhance drug-induced cell killing was expressed as a potentiation index (PI) equal to the ratio of the GI50 of CCT244747 alone: GI50 for CCT244747 in combination with the genotoxic agent (combination GI50). PI values more than 1.0 indicate potentiation of the genotoxic agent by CCT244747. Intracellular inhibition of CHK1 function was determined using a cell-based ELISA assay for G2 checkpoint abrogation (mitosis induction assay, MIA; ref. 27). The IC50 for G2 checkpoint abrogation (MIA) was determined using nocodazole as a positive control. The activity index (AI) was used as a measure of the compound's ability to induce mitosis relative to its toxicity (i.e., ratio of MIA IC50: 96-hour SRB GI50).

Western blotting

Immunoblotting was carried out using standard techniques (27). Briefly, cells or tumor homogenates were lysed in ice-cold lysis buffer and protein concentrations determined. Aliquots (50 μg) of protein were denatured in Laemmli loading buffer and separated on precast 10% or 16% TRIS-Glycine gels (Novex-Invitrogen). Proteins were transferred to polyvinylidene difluoride membranes, which were blocked and probed with 1° antibodies to pS296, pS317, pS345, and total CHK1; pY15 and total CDK1 and cleaved PARP (CST); pS199 H2AX and total H2AX (Upstate), and GAPDH (Chemicon) and detected using appropriate horse-radish peroxidase (HRPO)-labeled secondary antibodies. Proteins were visualized using enhanced chemiluminescence (Pierce, Thermo-Fisher) on Hyperfilm (GE Healthcare). Protein bands were quantified by densitometry using ImageQuant 5.0 software.

Cell-cycle analysis

Cell-cycle distribution was assessed using propidium iodide (PI) or bromodeoxyuridine (BrdUrd) and PI staining as previously described (27).

Pharmacokinetic and efficacy studies

Compound tolerability and pharmacokinetic studies were carried out in BALB/c mice (Charles River). Human tumor xenografts were established in Crtac-Ncr-Fox1 (nu) athymic mice and treated as previously described (27). Hemizygotic animals transgenic for TH-MYCN and predisposed to the spontaneous generation of aggressive neuroblastomas through over expression of human MYCN were bred and used for in vivo studies as previously described (29, 30). Briefly, hemizygous TH-MYCN animals carried a single copy of the transgene construct consisting of a human MYCN cDNA expressed under the control of the rat tyrosine hydroxylase promoter and flanked on the 3’ end by a rabbit β-globin enhancer element. Tumors commonly arose in the peridrenal and abdominal paraspinal sympathetic ganglia. Mice were monitored for tumor development and assigned on a rolling trial basis to CCT244747 or vehicle treatment when significant locoregional tumor was detected by palpation (at least 8 × 8 × 8 mm size at approximately 65 days of age).

For oral administration, CCT244747 was given in 5% dimethyl sulfoxide, 20% Tween 20, 65% PEG400, and 10% water at 0.01 mL/g at the doses indicated. Mice bearing MYCN neuroblastoma tumors were administered CCT244747 as a single agent, bolus dose (100 mg/kg p.o.) on 7 consecutive days. Neuroblastoma tumor size was assessed by MRI, and final tumor weights were measured at necropsy 24 hours after the last dose. In some animals, antitumor activity was determined by measuring tumor volume using MRI before and following treatment. This was conducted on a 7T Bruker horizontal bore micro imaging system (Bruker Instruments) using a 3-cm birdcage coil. Anatomical T2-weighted coronal images were acquired from 20 contiguous 1-mm thick slices through the mouse abdomen, from which tumor volumes were determined using segmentation from regions of interest drawn on each tumor-containing slice.

For combination studies, CCT244747 was administered p.o. to mice bearing established HT29 tumors 24 and 48 hours after cytotoxic drug administration. In the first study, gemcitabine was administered on days 0, 7, and 14 at 100 mg/kg i.v. and CCT244747 at 75 mg/kg p.o. on days 1, 2, 8, 9, 15, and 16. In a second study, irinotecan was administered on days 0, 4, and 8 at 25 mg/kg intraperitoneally and CCT244747 at 150 mg/kg p.o. on days 1, 2, 5, 6, 9, and 10. In the Calu6 xenograft model, gemcitabine was administered on days 0, 4, and 8 at 100 mg/kg i.v. and CCT244747 at 75 mg/kg p.o. on days 1, 2, 5, 6, 9, and 10. In the SW620 model, gemcitabine was administered on days 0, 4, and 8 at 100 mg/kg i.v. and CCT244747 at 75 mg/kg p.o. on days 1, 2, 5, 6, 9, and 10. The SN38 and gemcitabine doses used were the highest, minimally active concentrations in each tumor model to facilitate further potentiation with CCT244747. Doses of CCT244747 were the highest nontoxic concentrations achievable on each schedule. Initial treatment groups consisted of 6 mice and animals were inspected daily and tumor size and mouse body weight measured every 2 or 3 days. Tumor volume was determined from 2 orthogonal measurements and growth delay was calculated from individual growth curves at 300% tumor volume, a value that gave linear regrowth and through which all tumors grew. All mice were treated in accordance with the local and national animal welfare guidelines (31).

Pharmacokinetic analyses

Drugs were extracted from plasma and tissue homogenates using methanol-containing internal standard. CCT244747 concentrations were determined by liquid chromatography/tandem mass spectrometry (LC/MS-MS) with an Agilent Infinity 1290 binary pump and a 6410 triple quadrupole mass spectrometer. Pharmacokinetic parameters were calculated using noncompartmental analysis on Pharsight WinNonLin software version 5.2. Protein binding was carried out using ultrafiltration (10 μmol/L).
CCT244747 for 1 hour at 37°C. In vitro metabolism studies of 10 μmol/L compound were conducted using male CD1 mouse microsomes (Tebu-bio) for 30 minutes at 37°C with 1 mg/mL protein in the presence of NADPH and UDPGA with LC/MS-MS analysis as above.

Statistics
Statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001) was determined using an unpaired, one-tailed t test or one-way ANOVA and either Tukey or Dunnett test as appropriate with GraphPad Prism 5 software.

Results
Chemical structure and in vitro kinase activity of CCT244747
The chemical structure of CCT244747 is shown in Fig. 1A and a model of this compound bound into the ATP pocket of human CHK1 in Supplementary Fig. S2. This model was derived using constrained scaffold docking of CCT244747 into the SAR-020106 X-ray crystal structure (PDB 2ym8; ref. 32). It suggests that CCT244747 can retain key interactions in the ATP-binding site through hydrogen-bonding to Glu85 and Cys87 in the hinge region, the hydrogen-bonding of the nitrile to Lys38, and the dimethylamine situated in the ribose pocket, as noted for other 2-amino-pyrazine-5-carbonitrile CHK1 inhibitors (32).

In vitro kinase profiling showed that CCT244747 was a potent and highly selective inhibitor of recombinant human CHK1 (Supplementary Table S1) with an IC50 of 8 nmol/L. There was 75-fold selectivity against FLT3 (IC50 600 nmol/L) and more than 1,000-fold selectivity against the functionally important kinases CHK2 and CDK1 (IC50 > 10,000 nmol/L). Kinase profiling at 1 μmol/L CCT244747 showed some activity (>50% inhibition) against 8 kinases.
Clinical Cancer Research
Clin Cancer Res; 18(20) October 15, 2012

with a progressive loss of S and increase in S HT29 cells up to a concentration of 0.5 mol/L CCT244747 in SW620 cells (Fig. 1C and D, respectively). SN38 and CCT244747 in HT29 cells or gemcitabine and irinotecan antitumor activity in vivo.

CCT244747 overcomes genotoxic-induced S and G2 cell-cycle arrest

CHK1 has been implicated in stabilizing replication forks and maintaining G2 checkpoint integrity. As a part of our studies, we therefore explored the capacity of the CHK1 inhibitor CCT244747 to abrogate drug-induced cell-cycle checkpoints. The ability of CCT244747 to abolish a G2 arrest induced by etoposide in HT29 colon carcinoma cells was initially investigated as this forms the basis of the cellular CHK1 assay (see later). Figure 1B shows that there were minimal effects of CCT244747 alone on cell-cycle distribution at 0.5 mol/L for 24 hours. In contrast, acute etoposide exposure (25 μmol/L × 1 hour) caused a marked G2–M arrest at 24 hours (70.5% in G2–M). The addition of 0.5 μmol/L CCT244747 for 23 hours following acute etoposide treatment caused a substantial loss of G2–M cells (30%) with a corresponding increase in G1 (9.6%). There was a marked increase in cells trapped in S-phase but not actively incorporating BrdUrd (S0) over 24 hours, from 5% to 42.1%, potentially indicative of a cytotoxic event in S-phase. Similar results were obtained at 48 hours.

In contrast, CCT244747 had minimal effects alone up to 1 μmol/L for 24 hours in the SW620 colon carcinoma cell line (Fig. 1D). Gemcitabine (10 μmol/L × 24 hours) induced a marked S-phase arrest and the addition of CCT244747 overcame this arrest with a 28.8% reduction in S-phase, a small increase in G1 (4.4%) but a marked increase in S-phase (19%). At 48 hours, similar cell-cycle effects were observed but the S-phase population was more extensively induced by the combination, consistent with a delayed cytotoxic event. These observations provide clear evidence that CCT244747 can abolish both SN38 and gemcitabine-induced S- and G2–M-phase cell-cycle arrests, although with subtle differences in the kinetics.

Measurement of cellular CHK1 inhibition and potentiation of anticancer drug cytotoxicity by CCT244747

An ELISA-based cellular assay was used to measure functional CHK1 inhibition (27) giving IC50 ranging from 29 to 170 nmol/L for cellular G2 checkpoint abrogation (mitosis induction assay; MIA) in the 4 cell lines used (Table 1). The corresponding GI50 for this compound was between 0.33 and 3 μmol/L. The potent inhibition of cellular CHK1 function versus low cellular cytotoxicity resulted in activity indices (AI; ratio of GI50 checkpoint abrogation IC50: SRB GI50) of between 3.5 and 23 consistent with a good target selectivity. Table 1 summarizes these data and the ability of CCT244747 to enhance the cytotoxicity of numerous anticancer treatments in several different human tumor cell lines. With the exception of CDDP in HT29, CCT244747 significantly enhanced the cytotoxicity of all the treatments tested in all 4 cell lines, with more marked potentiation occurring with S-phase active drugs, such as the topoisomerase I inhibitor SN38 (the active metabolite of irinotecan), the antimitabolite gemcitabine (Supplementary Fig. S1), and the thymidylate synthase inhibitor 5-fluoro-2'-deoxyuridine (5FdU). Interestingly, there was minimal selective potentiation by CCT244747 of SN38 or gemcitabine cytotoxicity in a HPV16E6-transfected A549 or p53 recombinant knockout HCT116 cell line relative to the wild-type p53 controls (data not shown). On the basis of the results shown here and other published data on active genotoxic combinations with CHK1 inhibitors (14–17, 27), we evaluated the ability of CCT244747 to enhance gemcitabine and irinotecan antitumor activity in vivo.

CCT244747 inhibits CHK1 phosphorylation and cell-cycle biomarkers in vitro

To ensure that target inhibition has occurred in cells, it is important to monitor appropriate biomarker readouts such as the phosphorylation status of kinase-specific substrates. Figure 2A shows that SN38 induced S296 CHK1 autophosphorylation in HT29 cells after 24 hours and this was inhibited by combination with CCT244747 at ≥0.05 μmol/L with complete loss of signal at ≥0.5 μmol/L. Phosphorylation on S317 and S345 was markedly increased by SN38 exposure and these increases were reversed at ≥0.1 μmol/L. However, neither phosphorylation was completely abolished by up to 5 μmol/L CCT244747. Phosphorylation of the cell-cycle marker pY15 CDK1 was induced by SN38 treatment and this was substantially inhibited by combination with ≥0.5 μmol/L CCT244747. The inhibition of CHK1 autophosphorylation and CDK1 phosphorylation coincided with the induction of γ-H2AX (pS139 H2AX) and PARP cleavage, markers of DNA damage and apoptosis, respectively. Similar results were obtained with gemcitabine and CCT244747 combinations in SW620 cells (Fig. 2B), although SW620 cells may be slightly less sensitive than HT29 to CHK1 inhibition. Additional studies confirmed that a noncytotoxic concentration of 0.3 μmol/L CCT244747 was able to inhibit CHK1 activity in combination with either SN38 or gemcitabine and this was...
associated with an increase in DNA damage and apoptosis (Supplementary Fig. S3). Consequently, these results clearly show that CCT244747 can inhibit SN38- and gemcitabine-induced CHK1 activity in tumor cells and this correlates with the abrogation of cell-cycle arrest, induction of DNA damage, and apoptosis.

**Schedule dependency of CHK1 inhibitor enhanced gemcitabine cytotoxicity in vitro**

To investigate the mechanism of action of CHK1 inhibition and optimize in vivo combinations, a series of experiments was undertaken to determine the most efficacious scheduling of 2 structurally distinct CHK1 inhibitors, SAR-020106 (27) and CCT244747, on gemcitabine cytotoxicity in SW620 cells. This cell line and the drug combinations were selected because of their large potentiation indices (see Table 1; ref. 27). Supplementary Fig. S4A shows that SAR-020106 caused maximum potentiation of gemcitabine cytotoxicity following continuous genotoxic exposure for 48 hours or more. Exposures less than 24 hours resulted in minimal enhancement of gemcitabine activity. These data suggest that SAR-020106 could be administered 24 hours following gemcitabine and still maximally enhance gemcitabine cytotoxicity. It is possible that this schedule dependency was the result of synchronization of these cells following initial genotoxic drug exposure and that CHK1 inhibitor activity was maximized in the second cell cycle (24–48 hours following initial drug exposure). To test this hypothesis, SW620 cells were synchronized in M-phase by nocodazole treatment and subsequently released and exposed to gemcitabine in combination with SAR-020106 before S-phase entry for times to maximize activity in the first cell cycle (Supplementary Fig. S4B). The results in Supplementary Fig. S4C show that cell synchronization had minimal effects on the ability of SAR-020106 to enhance gemcitabine cytotoxicity. Supplementary Fig. S4D shows more detailed scheduling studies with gemcitabine and CCT244747, which confirm the requirement for continuous CHK1 inhibition for 24 to 48 hours following genotoxic administration for maximal enhancement of gemcitabine cytotoxicity in SW620 cells. Furthermore, the degree of potentiation was similar following either continuous or 24 hours delayed CCT244747 exposure, justifying a delayed CHK1 inhibitor treatment schedule in vivo. These data are consistent with the notion that a lethal event is induced in the second cell cycle following gemcitabine treatment and that prolonged CHK1 inhibitor contact (48 hours) will be required for maximum activity in vivo.

### Table 1. Summary of cellular CHK1 cytotoxicity and therapeutic activity of CCT244747 in combination with various genotoxic anticancer agents in human tumor cell lines

<table>
<thead>
<tr>
<th>Cells</th>
<th>MIA (μmol/L)</th>
<th>GI50 (μmol/L)</th>
<th>Genotoxic</th>
<th>Combination</th>
<th>Potentiation index (PI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HT29</td>
<td>0.029 ± 0.0031</td>
<td>0.62 ± 0.23</td>
<td>SN38</td>
<td>0.32 ± 0.022 (n = 4)</td>
<td>1.9 ± 0.14*** (n = 4)</td>
</tr>
<tr>
<td></td>
<td>(n = 4)</td>
<td></td>
<td>Gemcitabine</td>
<td>0.074 ± 0.014 (n = 4)</td>
<td>8.5 ± 1.6** (n = 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Etoposide</td>
<td>0.36 ± 0.13 (n = 4)</td>
<td>1.9 ± 0.63* (n = 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CDDP</td>
<td>0.34 ± 0.067 (n = 3)</td>
<td>1.8 ± 0.32 (n = 3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5FU</td>
<td>0.29 ± 0.029 (n = 3)</td>
<td>2.2 ± 0.2** (n = 3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5FdU</td>
<td>0.065 ± 0.0078 (n = 3)</td>
<td>9.6 ± 1.2** (n = 3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IR - 1 h</td>
<td>0.20 ± 0.021 (n = 4)</td>
<td>3.9 ± 0.32* (n = 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IR + 1 h</td>
<td>0.22 ± 0.059 (n = 4)</td>
<td>3.0 ± 0.67* (n = 4)</td>
</tr>
<tr>
<td>SW620</td>
<td>0.17 ± 0.0058</td>
<td>3.0 ± 1.2</td>
<td>SN38</td>
<td>1.2 ± 0.24 (n = 3)</td>
<td>2.6 ± 0.6* (n = 3)</td>
</tr>
<tr>
<td></td>
<td>(n = 3)</td>
<td></td>
<td>Gemcitabine</td>
<td>0.26 ± 0.05 (n = 5)</td>
<td>12.2 ± 2.7** (n = 5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Etoposide</td>
<td>0.68 ± 0.25 (n = 3)</td>
<td>4.9 ± 2.2* (n = 3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CDDP</td>
<td>0.73 ± 0.16 (n = 3)</td>
<td>4.2 ± 0.87* (n = 3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5FU</td>
<td>0.91 ± 0.20 (n = 3)</td>
<td>4.9 ± 0.8* (n = 3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5FdU</td>
<td>0.068 ± 0.019 (n = 3)</td>
<td>47 ± 14* (n = 3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IR - 1 h</td>
<td>0.71 ± 0.19 (n = 4)</td>
<td>4.5 ± 1.2* (n = 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IR + 1 h</td>
<td>0.66 ± 0.18 (n = 4)</td>
<td>4.9 ± 1.6* (n = 4)</td>
</tr>
<tr>
<td>MiaPaCa-2</td>
<td>0.044 ± 0.010</td>
<td>1.0 ± 0.29</td>
<td>SN38</td>
<td>0.21 ± 0.037 (n = 5)</td>
<td>5.0 ± 0.82** (n = 5)</td>
</tr>
<tr>
<td></td>
<td>(n = 3)</td>
<td></td>
<td>Gemcitabine</td>
<td>0.064 ± 0.023 (n = 5)</td>
<td>16 ± 6.3** (n = 5)</td>
</tr>
<tr>
<td>Calu6</td>
<td>0.094 ± 0.066</td>
<td>0.33 ± 0.051</td>
<td>SN38</td>
<td>0.24 ± 0.040 (n = 3)</td>
<td>1.4 ± 0.24* (n = 3)</td>
</tr>
<tr>
<td></td>
<td>(n = 3)</td>
<td></td>
<td>Gemcitabine</td>
<td>0.061 ± 0.010 (n = 3)</td>
<td>5.6 ± 0.96* (n = 3)</td>
</tr>
</tbody>
</table>

**NOTE:** GI50 checkpoint abrogation (MIA, IC50), cytotoxicity (SRB GI50), and activity index (AI) values were determined as described in Material and Methods. Potentiation index (PI) is the ratio of SRB GI50/combination GI50, where combination GI50 is the concentration of CCT244747 that causes 50% inhibition of cell growth in combination with a fixed (GI50) concentration of the cytotoxic agent. PI values >1 indicate potentiation of the cytotoxic agent. Values are mean ± SD of n independent determinations. Statistical significance: *, P < 0.05; **, P < 0.01; and ***, P < 0.001.
Pharmacokinetics of CCT244747 in mice and human tumor xenografts

The pharmacokinetic properties of CCT244747 alone were determined in BALB/c mice to ensure that adequate exposure could be achieved for CHK1 inhibition in vivo (Fig. 3A). Following 10 mg/kg i.v. administration, CCT244747 reached a peak plasma concentration of 3.62 µmol/L at 5 minutes with a relatively short half-life of 0.67 hours giving an AUC0–¥ of 3.93 µmol/L h. In contrast, the peak plasma concentration was only 0.98 µmol/L following 10 mg/kg oral administration, but the half-life was longer at 0.92 hours, giving an AUC0–¥ of 2.43 µmol/L h. Oral bioavailability was therefore 62% and clearance 6.2 l/h/kg. Mouse plasma protein binding was 75.6% and microsomal metabolism was 45%. Figure 3B shows that there was a dose-dependent increase in the plasma concentration of CCT244747 up to 150 mg/kg p.o. at 12 and 24 hours in tumor-bearing mice treated with gemcitabine (100 mg/kg i.v.). Corresponding HT29 tumor concentrations were also dose-dependent over a similar dose range and there was a clear evidence of enhanced tumor drug uptake relative to plasma with tumor/plasma ratios 47 ± 21-fold higher than plasma at 12 hours following 100 mg/kg p.o. (mean ± SD, n = 3). There was no apparent effect of gemcitabine (100 mg/kg i.v.) on CCT244747 pharmacokinetics in mice (data not shown). Figure 3C and D show that gemcitabine induced S296 CHK1 autophosphorylation in HT29 xenografts. Combination with CCT244747 significantly decreased this phosphorylation (P < 0.05). In comparison, the gemcitabine-induced increase in S317 CHK1 and Y15 CDK1 phosphorylation was less markedly inhibited by CCT244747 in keeping with the in vitro observations (Fig. 2). Perhaps more importantly, these studies indicated that potentially active tumor concentrations of CCT244747 could be achieved for at least 24 hours following oral administration in vivo and this was associated with a significant decrease in CHK1 activity.

Antitumor and pharmacodynamic effects of CCT244747 combined with irinotecan and gemcitabine

In all combination antitumor studies, each cycle of treatment consisted of a single dose of a genotoxic followed by 2 doses of CCT244747, 24 and 48 hours later, in keeping with the results of the in vitro scheduling studies. Figure 4 and Supplementary Table S2 summarize the antitumor activity of CCT244747 in combination with irinotecan or gemcitabine in several human tumor xenograft models. Figure 4A shows a minimal effect of CCT244747 alone in HT29 xenografts and a slight but insignificant growth delay of 2.3 days with gemcitabine alone. The addition of CCT244747 to gemcitabine increased the growth delay to 11.4 days giving a statistically significant difference of 9.1
Figure 3. The pharmacokinetic characteristics and pharmacodynamic effects of CCT244747 alone or in combination with gemcitabine in vivo. A, plasma pharmacokinetics of a single bolus dose of CCT244747 alone (10 mg/kg either i.v. or p.o.) in BALB/c mice. B, concentrations of CCT244747 occurring in mouse plasma and HT29 human tumor xenografts treated with gemcitabine (100 mg/kg i.v.) measured 12 and 24 hours following administration of different doses of CCT244747 p.o. The horizontal dotted line represents the concentration of CCT244747 required for G2 checkpoint abrogation in vitro (MIA, 29 nmol/L, see Table 1). C, biomarker changes induced by gemcitabine treatment alone (100 mg/kg i.v.) or in combination with CCT244747 (100 or 150 mg/kg p.o.) measured in HT29 xenografts 24 hours following final CCT244747 treatment. Protein expression was characterized by Western blotting as described in Materials and Methods and in the legend to Fig. 2. D, quantification of the immunoblots shown in C. Values are mean ± SE, n = 3. Statistical analysis was by one-way ANOVA using Dunnett correction; *, P < 0.05 indicates a significant difference from gemcitabine treatment alone.
spontaneously in a hemizygotic transgenic mouse model characterized by over expression of MYCN (TH-MYCN) (29). Figure 5A shows that CCT244747 caused significant tumor shrinkage ($P < 0.001$) compared with vehicle-treated controls following 7 days of continuous treatment at 100 mg/kg p.o.. CCT244747 treatment caused marked reduction in neuroblastoma tumor volume as assessed by MRI (e.g., 79% volume reduction, see Fig. 5B) and the treatment was well tolerated with no drug-related morbidity, consistent with previous tolerability studies (Supplementary Fig. S5). These data confirm the antitumor activity of CCT244747 as a single agent in a molecularly defined MYCN-driven model of neuroblastoma and warrant further investigation.

**Discussion**

CCT244747 is a novel potent, highly selective, and orally bioavailable CHK1 inhibitor, which is a considerable improvement over our previous inhibitor SAR-020106 (27) and represents the first structural disclosure of an orally active CHK1 inhibitor. Kinetic and modeling studies have established that CCT244747 is an ATP-competitive inhibitor of recombinant human CHK1. The selectivity profile of CCT244747 shows minimal cross-reactivity with CHK2 and CDK1. Both of these characteristics were deemed desirable as we and others have shown that CHK2 inhibition seems to have limited therapeutic potential (5, 33) and both CHK2 and CDK1 inhibition have been shown to antagonize the ability of CHK1 inhibitors to abrogate checkpoints (34). Some cross-reactivity with the tyrosine kinase inhibitors FLT3, IRAK1, and RSK1 and RSK2 at 1 µmol/L was noted and correspondingly greater kinase inhibition occurred at 10 µmol/L, although this concentration of free drug is unlikely to be achieved or maintained in vivo.

Cellular CHK1 inhibition was measured using an ELISA-based $G_2$ checkpoint abrogation/mitotic induction assay...
CHK1 Inhibitor CCT244747 Pharmacology and Therapeutic Activity

Figure 5. Single-agent antitumor activity of CCT244747 in a MYCN-driven transgenic mouse model of neuroblastoma (TH-MYCN). A, effect of CCT244747 treatment (100 mg/kg p.o. x 7 days) on final neuroblastoma tumor weight at necropsy relative to vehicle-treated controls. Values are mean ± SE for 6 mice. Statistical differences were assessed using a t-test; *** P < 0.001. B, T2-weighted MR images of a TH-MYCN neuroblastoma tumor before (left) and after treatment with CCT244747 (100 mg/kg p.o. x 7 days). The pre- and posttreatment tumor volumes were calculated as 1,960 mm³ and 417 mm³, respectively, representing a 79% decrease in tumor volume. Tissues are: t, tumor; k, kidney; and sb, small bowel. Tumor size was assessed as described in Materials and Methods.

(MIA), whereas toxicity was determined using a growth delay endpoint (GI₃₀), the ratio of these 2 values giving a useful therapeutic window of 18-21-fold in SW620 and HT29 colon carcinoma cells, respectively. CCT244747 enhanced the cytotoxicity of several anticancer drugs and ionizing radiation. The latter was independent of whether the inhibitor was given before or after radiation, suggesting a potential effect on either checkpoint abrogation or DNA repair rather than increased radiation damage per se. Similar results have been obtained with other CHK1 inhibitors in vitro (17, 35, 36). Interestingly, the most marked potentiation by CCT244747 was with gemcitabine or 5fluorouracil, both of which target DNA synthesis through inhibition of ribonucleotide reductase or thymidylate synthase, respectively, and frequently lead to nucleotide misincorporation (37-39). This in turn may explain the requirement with gemcitabine for CHK1 inhibitor exposure 24 to 48 hours after genotoxic exposure, as the initial misincorporation may undergo subsequent processing in the second cell division giving rise to a lethal event consistent with the increased S-phase population in the cell-cycle results (38, 40, 41). Several other CHK1 inhibitors also require exposure for 24 to 48 hours following gemcitabine or camptothecin treatment in vitro (15, 17, 41). However, this may not be a universal observation and could depend on the ability of the different CHK1 inhibitors to deplete total CHK1 protein through S45 CHK1 phosphorylation and ubiquitination with subsequent compromised checkpoint recovery (42). Other factors could also contribute to the scheduling requirements such as the selectivity profile of the CHK1 inhibitor, the genotoxic agent involved, and the cell line under investigation leading to different effects on transcription and DNA repair versus checkpoint abrogation. The role of p53 in enhancing the activity of CHK1 inhibitors in combination with genotoxic drugs is also unclear with some reports suggesting that p53 functional status does not always affect either combinations or single-agent CHK1 inhibitor activity in agreement with our observations (20, 43).

We have characterized the pharmacokinetic and pharmacodynamic relationships between drug exposure and the modulation of a number of potentially useful biomarkers for assessing CHK1 inhibition both in vitro and in vivo. Such studies constitute an important component of drug discovery and ensure that target inhibition can be monitored throughout the preclinical and clinical drug evaluation program via a "pharmacologic audit trail" (44). Pharmacokinetic studies established that CCT244747 was concentrated or retained in tumor tissue following oral administration and adequate exposures for CHK1 inhibition could be achieved and maintained using this route. Studies with SN38 and gemcitabine in HT29 and SW620 cells showed that S296 CHK1 autophosphorylation was markedly enhanced together with induction of phosphorylation on S317 and S345. Combination with CCT244747 abolished S296 CHK1 phosphorylation but only partially inhibited the pS317 and pS345 signals, which may require prolonged exposure for complete inhibition (see Fig. 4B). Substantial induction of pY15 CDK1 (a cell-cycle biomarker) was also observed following genotoxic exposure in vitro and this signal was abolished by CCT244747, consistent with abrogation of a genotoxic-induced cell-cycle arrest. The observation that pS139 H2AX and PARP cleavage occurred at concentrations of CCT244747, which abolished pS296 CHK1 and pY15 CDK1, suggest that CHK1 inhibition was associated with DNA damage and enhanced apoptosis. Subsequent in vivo studies confirmed that CCT244747 could inhibit a gemcitabine-induced increase in both pS296 CHK1 and pY15 CDK1 in tumor xenograft tissues using treatment regimens that induced significant antitumor activity. These studies support the use of pS296 CHK1 as a direct readout of CHK1 inhibition and pY15 CDK1 as a biomarker of cell-cycle modulation. However, it is likely that several biomarkers will be required to ensure the fidelity of CHK1 inhibition in the clinical setting and these might include downstream readouts of DNA damage such as RAD51 foci and γ-H2AX as well as apoptosis markers, for example, cleaved PARP and caspase-3 (12, 27, 29, 34, 36).

Efficacy studies showed that CCT244747 could significantly enhance the growth inhibitory properties of irinotecan and gemcitabine in several human tumor xenograft models. Moreover, the use of CCT244747 alone or in...
combination was well tolerated with minimal body weight loss. The precise mechanism of this enhanced antitumor activity is still unclear and may involve replication fork collapse, checkpoint abrogation, and inhibition of DNA repair (8, 34, 36, 45). Nevertheless, our studies clearly show that the CHK1 inhibitor needs to be present for at least 24 to 48 hours following genotoxic drug administration, possibly requiring multiple administrations, which the oral activity of CCT244747 will facilitate.

Several recent publications have indicated that CHK1 inhibitors may have single-agent activity in tumors exhibiting marked genomic instability or specific molecular defects (17, 21, 24). Using a genetically defined MYCN-driven murine transgenic model of neuroblastoma in which tumors arise spontaneously, we have clearly shown that CCT244747 has marked single agent, antitumor activity. Importantly this model recapitulates the major clinicopathologic features of high-risk MYCN-amplified neuroblastoma in humans, which is characterized by an extremely poor response to conventional chemotherapeutics (29). In addition, the chronic oral administration of CCT244747 was well tolerated and caused marked regression of this extremely aggressive tumor. These data are consistent with the observations of Cole and colleagues in MYCN-driven neuroblastoma (24) and the reported single-agent activity of CHK1 inhibitors and CHK1 RNAi in C-MYC–driven lymphoma cells (23), in AML (22), and several human tumor cell lines (20). This may be explained by MYC oncogene expression causing increased replicative stress and enhanced replication origin firing with an associated need for elevated CHK1 to avoid catastrophic replication fork collapse (1, 7, 18, 19, 21). CHK1 inhibition seems to enhance CDK activity with attendant replication fork collapse and increased DNA double-strand breaks giving rise to enhanced tumor cell killing (4, 46). Inhibition of CHK1 could compromise homologous recombination repair, through indirectly inhibiting RAD51, a CHK1 substrate and this may also be therapeutically advantageous (8). It is further interesting to note that other G2 checkpoint abrogators such as the WEE1 inhibitor MK1775 also show single-agent activity through deregulation of CDKs in tumors (46, 47).

Finally, our data show that CCT244747 is a novel potent, highly selective, and orally active CHK1 inhibitor that significantly enhances the antitumor activity of gemcitabine and irinotecan in a variety of human tumor xenografts. Biomarker studies indicate that this enhanced antitumor activity is associated with CHK1 inhibition and cell-cycle checkpoint abrogation. Moreover, CCT244747 also showed marked antitumor activity as a single agent in MYCN-driven neuroblastoma. This report is the first disclosure of a highly selective, orally active CHK1 inhibitor and supports further development of these compounds.

Disclosure of Potential Conflicts of Interest

M.I. Walton, P.D. Eve, A. Hayes, M.R. Valenti, A.K. De Haven Brandon, G. Box, A. Hallsworth, E.L. Smith, K.J. Boxall, M. Lainchbury, T.P. Matthews, Y. Jamin, S.P. Robinson, G.W. Aberne, L. Chesler, S.A. Eccles, F.I. Raynaud, J. Collins, and M.D. Garrett are current or former employees of The Institute of Cancer Research, which has a commercial interest in CHK1 inhibitors. J.C. Reader is an employee of Sarum Ltd, which has a commercial interest in CHK1 inhibitors. Sarum Ltd is a wholly owned subsidiary of Sarum Holdings PLC, of which J.C. Reader is a shareholder. Both Sarum and The Institute of Cancer Research have been involved in a commercial collaboration with Cancer Research Technology Ltd (CRT) to discover and develop inhibitors of CHK1.

Authors’ Contributions


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M.I. Walton, P.D. Eve, A. Hayes, M. Valenti, A. De Haven Brandon, G.M. Box, A. Hallsworth, E.L. Smith, T.P. Matthews, Y. Jamin, W. Aberne, L. Chesler, S.A. Eccles


Writing, review, and/or revision of the manuscript: M.I. Walton, J.C. Reader, L. Chesler, S.A. Eccles, J. Collins, M.D. Garrett

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.I. Walton, M. Valenti, W. Aberne


Acknowledgments

The authors thank Gowri Vijayaraghavan for helping with flow cytometry studies, Nathan Brown with modeling studies, and useful discussions with other members of the Cell Cycle Control Team.

Grant Support

This work was supported by Cancer Research UK [CIHK] grant number C309/A8274, C309/A11566, Cancer Research UK and EPSRC Cancer Imaging Centre, in association with the MRC and Department of Health (England) grant number C1060/A10334, The Wellcome Trust, grant number 091763/Z/10/Z, and also NHS funding to the NIHR Biomedical Research Centre.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 23, 2012; revised August 4, 2012; accepted August 7, 2012; published OnlineFirst August 28, 2012.

References


CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

Mike I. Walton, Paul D. Eve, Angela Hayes, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-12-1322

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/08/28/1078-0432.CCR-12-1322.DC1

Cited articles
This article cites 46 articles, 18 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/18/20/5650.full#ref-list-1

Citing articles
This article has been cited by 13 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/18/20/5650.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.